血脂、血糖、腰围水平与胆结石发病的相关性分析

目的 探讨肥胖、高血脂、高血糖与胆结石形成的关系.方法 对在我院就诊的114名胆结石病员和随机抽取的105名常规体检的职工进行肝胆B超检查、腰围及血糖血脂检测结果,进行统计学分析.结果 胆结石组与对照组甘油三酯含量相比有非常显著性差异(P<0.01);总胆固醇含量、血糖含量、腰围值相比有显著性差异(P<0.05).结论 胆结石的发生与全身脂类糖类代谢异常有关.预防和减少胆结石的发生,既要纠正已存在的高血脂症和/或高血糖症,又要防止体重过度增加.

757例体检人群血脂水平调查分析

近年来,由于生活水平的提高以及生活方式的改变,国人血脂水平呈升高趋势,尤以中青年人群更为明显.血脂水平升高会导致高脂血症,而高脂血症是动脉粥样硬化性心脑血管疾病危险因素(高脂血症、高血压、吸烟、内分泌紊乱和遗传)中的首要危险因子.因而早期检查血脂水平,并积极降脂治疗是预防动脉粥样硬化的重要环节.本文报告757例体检人群血脂结果和不同年龄组分布特点,为防治工作提供实验依据.

血尿酸水平与急性ST段抬高型心肌梗死的相关性研究

目的：探讨急性ST段抬高型心肌梗死(STEMI)与血尿酸水平的相关性。方法收集中国人民解放军总医院2012年1月至2014年10月因STEMI行急诊冠状动脉介入(PCI)的357例患者的临床资料，其中血尿酸正常组患者261例，高尿酸血症组患者96例，比较所有患者血尿酸水平与冠脉病变支数的关系以及两组患者的基线资料、心脏功能和院内死亡率等。结果高尿酸血症组患者的体重、体质指数、心率、高血压病患病率、血脂异常患病率、胆固醇、甘油三酯、低密度脂蛋白胆固醇水平以及左室舒张末内径(LVEDD)均较血尿酸正常组高，差异均有统计学意义(P<0.05)，其高密度脂蛋白胆固醇水平及左室射血分数(LVEF)均较血尿酸正常组低，差异均有统计学意义(P<0.05)，两组患者的住院时间及院内死亡率差异均无统计学意义(P>0.05)；血尿酸水平与胆固醇、甘油三酯及低密度脂蛋白胆固醇水平均呈正相关(P<0.05)，与高密度脂蛋白胆固醇水平呈负相关(P<0.05)；冠状动脉单、双支及三支病变患者的血尿酸水平分别为(320.23±105.79)μmol/L、(345.14±88.97)μmol/L、(375.32±113.38)μmol/L，呈递增关系，且各组血尿酸水平的差异有统计学意义(F=8.259，P=0.000)。结论在急性STEMI患者中，高尿酸血症患者冠脉病变程度更严重,且心功能差，血脂、血糖代谢紊乱水平高。

Objective:To observe the effect of atorvastatin combined with ezetimibe on the levels of urine protein, PCT, serum lipid, and hs-CRP in patients with acute coronary syndrome (ACS). Methods:A total of 90 ACS patients who were admitted in our hospital were included in the study and randomized into A, B, and C groups with 30 cases in each group. The patients in A group were given atorvastatin (20 mg/d, a maintenance dose), the patients in B group were given atorvastatin (40 mg/d, a load dose), while the patients in C group were given atorvastatin in a load dose combined with ezetimibe (10 mg/d). The changes of 24 h UMA, PCT, serum lipid, and hs-CRP after two-week treatment in the three groups were observed, and the adverse reactions in the three groups were observed.Results:The improvements of urine protein, PCT, and serum hs-CRP concentration after treatment in B and C groups were significantly superior to those in A group (P<0.05). The improvements of urine protein, PCT, and serum hs-CRP concentration after treatment in C group were significantly superior to those in A and B groups (P<0.05). The levels of TC and LDL-C after treatment in B and C groups were significantly reduced when compared with those before treatment (P<0.05). The levels of TC and LDL-C after treatment in group A were not statistically different from those before treatment (P>0.05). No obviously adverse reactions occurred in the three groups.Conclusions:Atorvastatin in a load dose combined with ezetimibe can significantly adjust the levels of UMA, PCT, and serum lipid in ACS patients, reduce the concentrations of inflammatory factors, and play an active role in the treatment of ACS.